Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate

WILMINGTON, Del., March 6, 2015 /PRNewswire/ -- Lucerne Biosciences, LLC announced today the U.S. Patent and Trademark Office's publication of U.S. Patent Application No. 14/464,249 entitled "Method of Treating Binge Eating Disorder."  The '249 Patent Application features claimed methods of "informing a user" that "lisdexamfetamine dimesylate ('LDX') may be used to treat Binge Eating Disorder ('BED')," including by reference to "a package insert," "information material," or "flyer or an advertisement," as well as by presentation of "information at a seminar, conference or other educational presentation," or by "a conversation between a pharmaceutical sales representative and medical care worker." Additional claimed methods of treating BED with LDX featured in the '249 Application encompass conducting a clinical trial on the efficacy of LDX for treating BED and informing a purchaser that LDX is efficacious for treating BED.

About Lucerne Biosciences, LLC

Lucerne Biosciences is a privately-held pharmaceutical development company that wholly owns the '249 Patent Application, as well as U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder." The '813 Patent features claims that involve the use of LDX for the treatment of patients diagnosed with BED.   

About BED 

BED is a serious eating disorder. BED's DSM-V^® criteria include eating unusually large amounts of food in a discrete period of time (i.e., within a 2 hour period) and a sense of lack of control over eating during the episode with binge eating episodes associated with at least three (or more) of the following: eating much more rapidly than normal; eating until feeling uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed or very guilty after overeating. Additionally, marked distress regarding the binge eating is present and the binge eating occurs, on average, at least once a week for 3 months; also, the binge eating does not occur exclusively during the course of bulimia nervosa or anorexia nervosa.

About Lisdexamfetamine Dimesylate

Lisdexamfetamine dimesylate (l-lysine-d-amphetamine) is an amphetamine prodrug approved by the FDA to treat moderate to severe BED in adults. LDX is also FDA approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Supplemental Information on Lucerne Biosciences' Intellectual Property

The '249 Patent Application is available at: https://app.box.com/s/a308132casvzw78e2vitf9z90r0fmcbx and the '813 Patent is available at: https://app.box.com/s/5euyutbdi2hpuqgru5wb7zegjvq17hnh.

Media Contact:
Louis Sanfilippo, MD
203-521-1143

U.S. Patent Application No. 14/464,249/ Method of Treating Binge Eating Disorder
U.S. Patent No. 8,318,813/ Method of Treating Binge Eating Disorder

SOURCE Lucerne Biosciences, LLC